Zobrazeno 1 - 10
of 16
pro vyhledávání: '"P C, Gotzsche"'
Autor:
Jan P. Vandenbroucke, Erik von Elm, Douglas G. Altman, Peter C. Gotzsche, Cynthia D. Mulrow, Stuart J. Pocock, Charles Poole, James J. Schlesselman, Matthias Egger
Publikováno v:
Вопросы современной педиатрии, Vol 21, Iss 3, Pp 173-208 (2022)
Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the generalisability of its results. Taking into acc
Externí odkaz:
https://doaj.org/article/329d44bfb4814e1b8b91068b8b1f4ec0
Publikováno v:
International Journal of Epidemiology. 37:1217-1219
Autor:
H K, Johansen, P C, Gotzsche
Publikováno v:
The Cochrane database of systematic reviews. (3)
Systemic fungal infection is considered to be an important cause of morbidity and mortality in cancer patients, particularly those with neutropenia. Antifungal drugs are often given prophylactically, or to patients with persistent fever.To compare th
Publikováno v:
The Cochrane database of systematic reviews. (2)
The major allergen in house dust comes from mites. Chemical, physical and combined methods of reducing mite allergen levels are intended to reduce asthma symptoms in people who are sensitive to house dust mites.The objective of this review was to ass
Autor:
P C, Gotzsche
Publikováno v:
The Cochrane database of systematic reviews. (2)
Somatostatin and its derivative, octreotide, are often used for emergency treatment of bleeding oesophageal varices in patients with cirrhosis of the liver. The placebo controlled trials have shown varying results, however, and their power has been q
Publikováno v:
Revista Española de Quimioterapia; 2016 supplement, Vol. 29, p9-12, 4p
Publikováno v:
BMJ. 315:488-489
Autor:
P. C Gotzsche
Publikováno v:
Journal of Medical Ethics. 21:190-191
Autor:
P. C Gotzsche
Publikováno v:
BMJ. 323:1131-1131
Publikováno v:
BMJ. 321:568-568
Editor—Gotzsche's review on non-steroidal anti-inflammatory drugs contains some inconsistencies that we would like to highlight.1 In the summary section on interventions Gotzsche states that H2 blockers are likely to be beneficial in high risk pati